Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled double-blind randomized phase II study of PC-SOD for chemotherapy-induced peripheral neuropathy in ovarian cancer patients receiving TC therapy as postoperative adjuvant chemotherapy
jRCT2031240306Phase 2Active, not recruiting
- Sponsor
- LTT Bio-Pharma Co., Ltd.
- Start
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing PC-SOD arm with Placebo arm (2 arms). Primary endpoint: Incidence of chemotherapy-induced peripheral neuropathy. Started Aug 2024; status: active, not recruiting.
02
Drugs
lecithinized superoxide dismutase
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCT2031240306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240306.